CTC-EXPRESS: A prospective observational study for CTC biomarker Expression and cfDNA/cfRNA assessment in metastatic breast cancer

DNA down to 1ppm and below without false positives.Testing patient material confirmed the technology's ability to detect ctDNA at comparably low levels. Conclusion:We have demonstrated the ability to detect MRD at low levels using a novel technology and shown that the approach is compatible with both Illumina and Ultima whole genome sequencing.Further development and testing on contrived and patient material are ongoing.